Tak-285

CAS No.	871026-44-7
MDL No.	MFCD22124520
MF	C₂₆H₂₅ClF₃N₅O₃
MW	548.00
InChI Key	ZYQXEVJIFYIBHZ-UHFFFAOYSA-N

CUSTOM SYNTHESIS PRECLINICAL SUPPORT

Pricing & Availability

Pack Size	Purity	Price	Availability	Action
-	-	On Request	On Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.	871026-44-7
Product Name	Tak-285

Biological Targets

EGFR·ERBB2

Associated Conditions

cancer

* The information provided here is compiled from public sources and is for reference only.

Tak-285

CAS No.	871026-44-7
MDL No.	MFCD22124520
MF	C₂₆H₂₅ClF₃N₅O₃
MW	548.00
InChI Key	ZYQXEVJIFYIBHZ-UHFFFAOYSA-N

CUSTOM SYNTHESIS PRECLINICAL SUPPORT

Pricing & Availability

Pack Size	Purity	Price	Availability	Action
-	-	On Request	On Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.	871026-44-7
Product Name	Tak-285

Biological Targets

EGFR·ERBB2

Associated Conditions

cancer

* The information provided here is compiled from public sources and is for reference only.

Tak-285

Pricing & Availability

Product Information

Biological Profile

Properties

Biological Targets

Associated Conditions

Tak-285

Pricing & Availability

Product Information

Biological Profile

Properties

Biological Targets

Associated Conditions

Documentation

Tak-285

Pricing & Availability

Product Information

Biological Profile

Properties

Biological Targets

Associated Conditions

Related Articles

Design and synthesis of pyrrolo[3,2-d]pyrimidine human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors: exploration of novel back-pocket binders.

Phase I first-in-human study of TAK-285, a novel investigational dual HER2/EGFR inhibitor, in cancer patients.

Verification of brain penetration of the unbound fraction of a novel HER2/EGFR dual kinase inhibitor (TAK-285) by microdialysis in rats.

Design and synthesis of novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors bearing a pyrrolo[3,2-d]pyrimidine scaffold.

Tak-285

Pricing & Availability

Product Information

Biological Profile

Properties

Biological Targets

Associated Conditions

Related Articles

Design and synthesis of pyrrolo[3,2-d]pyrimidine human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors: exploration of novel back-pocket binders.

Phase I first-in-human study of TAK-285, a novel investigational dual HER2/EGFR inhibitor, in cancer patients.

Verification of brain penetration of the unbound fraction of a novel HER2/EGFR dual kinase inhibitor (TAK-285) by microdialysis in rats.

Design and synthesis of novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors bearing a pyrrolo[3,2-d]pyrimidine scaffold.

Documentation